ArticleBMJ open2024

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.

Gavin Brittain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.